Sinopharm Tech Holdings Limited (HKG:8156)
Hong Kong · Delayed Price · Currency is HKD 0.3300
+0.0550 (20.00%)
Mar 6, 2026, 2:09 PM HKT
Sinopharm Tech Holdings Income Statement
Financials in millions HKD. Fiscal year is July - June.
Millions HKD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 69.12 | 61.25 | 41.28 | 42.84 | 40.99 | 77.81 | |
Revenue Growth (YoY) | 47.91% | 48.39% | -3.65% | 4.52% | -47.33% | -53.11% |
Cost of Revenue | 56.07 | 47.02 | 36.26 | 37.37 | 39.22 | 58.59 |
Gross Profit | 13.05 | 14.23 | 5.02 | 5.47 | 1.77 | 19.23 |
Selling, General & Admin | 11.32 | 12.93 | 14.18 | 21.47 | 42.43 | 62.22 |
Other Operating Expenses | 0.9 | - | - | - | - | - |
Operating Expenses | 20.35 | 21.07 | 15.42 | 20.59 | 76.39 | 75.08 |
Operating Income | -7.3 | -6.84 | -10.4 | -15.12 | -74.62 | -55.85 |
Interest Expense | -4.61 | -5.85 | -23.93 | -8.57 | -16.41 | -14.55 |
Interest & Investment Income | 0 | 0 | 0.08 | 0 | 0 | 0 |
Earnings From Equity Investments | - | - | - | 0.19 | -0.15 | 3.59 |
Other Non Operating Income (Expenses) | -0.29 | -0.29 | 0.26 | 31.19 | 3.84 | 4.6 |
EBT Excluding Unusual Items | -12.2 | -12.97 | -33.99 | 7.68 | -87.34 | -62.21 |
Impairment of Goodwill | - | - | - | - | -12.31 | -33.83 |
Gain (Loss) on Sale of Investments | 1.1 | 1.1 | -2.73 | -18.53 | -21.89 | - |
Gain (Loss) on Sale of Assets | 6.93 | 6.93 | 16.56 | - | 8.69 | 0.37 |
Asset Writedown | - | - | - | - | -8.13 | -4.6 |
Other Unusual Items | 3.86 | 3.86 | -0.16 | - | 26.82 | -10.8 |
Pretax Income | -0.3 | -1.08 | -20.33 | -10.85 | -94.16 | -111.06 |
Income Tax Expense | 0.42 | 0.29 | 0.08 | -1.31 | -0.39 | -0.56 |
Earnings From Continuing Operations | -0.72 | -1.37 | -20.42 | -9.54 | -93.77 | -110.51 |
Earnings From Discontinued Operations | - | - | 0.39 | -0.56 | - | - |
Net Income to Company | -0.72 | -1.37 | -20.03 | -10.1 | -93.77 | -110.51 |
Minority Interest in Earnings | 1.69 | 0.5 | 0.33 | -0.54 | 5.77 | 4.17 |
Net Income | 0.97 | -0.87 | -19.7 | -10.64 | -88 | -106.34 |
Net Income to Common | 0.97 | -0.87 | -19.7 | -10.64 | -88 | -106.34 |
Shares Outstanding (Basic) | 655 | 465 | 184 | 183 | 180 | 172 |
Shares Outstanding (Diluted) | 655 | 465 | 184 | 183 | 180 | 172 |
Shares Change (YoY) | 208.38% | 153.03% | 0.45% | 1.66% | 4.59% | 4.39% |
EPS (Basic) | 0.00 | -0.00 | -0.11 | -0.06 | -0.49 | -0.62 |
EPS (Diluted) | 0.00 | -0.00 | -0.11 | -0.06 | -0.49 | -0.62 |
Free Cash Flow | -2.93 | -5.7 | -12.58 | 4.73 | -36.89 | -16.33 |
Free Cash Flow Per Share | -0.00 | -0.01 | -0.07 | 0.03 | -0.20 | -0.10 |
Gross Margin | 18.88% | 23.23% | 12.16% | 12.77% | 4.32% | 24.71% |
Operating Margin | -10.56% | -11.16% | -25.20% | -35.29% | -182.06% | -71.78% |
Profit Margin | 1.40% | -1.42% | -47.72% | -24.83% | -214.71% | -136.66% |
Free Cash Flow Margin | -4.24% | -9.30% | -30.48% | 11.05% | -90.00% | -20.98% |
EBITDA | -6.59 | -6.12 | -9.76 | -13.91 | -73.3 | -50.54 |
EBITDA Margin | -9.54% | -9.99% | -23.66% | -32.48% | -178.84% | -64.95% |
D&A For EBITDA | 0.71 | 0.72 | 0.64 | 1.21 | 1.32 | 5.31 |
EBIT | -7.3 | -6.84 | -10.4 | -15.12 | -74.62 | -55.85 |
EBIT Margin | -10.56% | -11.16% | -25.20% | -35.29% | -182.06% | -71.78% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.